Cardiovascular Systems (CSII) Tops Q2 EPS by 3c, Offers Q3 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Leerink Partners Cut Price Target on Cardiovascular Systems (CSII) Following Disappointing 2Q and 3Q Guidance
January 22, 2016 9:22 AM ESTLeerink Partners maintained a Market Perform rating on Cardiovascular Systems (NASDAQ: CSII), and cut the price target to $13.00 (from $17.00), following the company's 2Q earnings report. For F2Q16, CSII reported sales of $41.4M, ~$2M below consensus. Also, management guided F3Q16 revenues well below consensus, yet again, at $40.5M-$42.0M vs. the Street at $46.1M. The guidance indicated what appears to be a more protracted impact than originally expected from the ongoing... More
Needham & Company Downgrades Cardiovascular Systems (CSII) to Underperform
January 22, 2016 7:34 AM ESTNeedham & Company downgraded Cardiovascular Systems (NASDAQ: CSII) from Buy to Underperform, saying positive revenue growth may be a year away.
Analyst Mike Matson commented, "CSII's F2Q16 revenue missed and EPS beat consensus and management guided below consensus for F2Q16. We are... More
